🔍

Emrock Corporation Ltd (531676)

📊 BSE: 531676 🏢 Packaged Foods 📢 Latest filing: 05 Oct 2026 📝 Analysis written: 13 Nov 2025

Latest quarterly results (Q1 FY27)

In its latest reported quarter, Q1 FY27, Emrock's revenue was ₹0.4 Cr (+199.1% year on year, -52.3% on the previous quarter), and net profit ₹0.2 Cr (+90.1% year on year); the operating margin was 49.8%.

Q1 FY27 (₹ Cr)	Value	YoY vs Q1 FY26	QoQ
Revenue	₹0.4	+199.1%	-52.3%
Operating profit	₹0.2	+272.5%	-36.1%
Net profit	₹0.2	+90.1%	-53.6%
EPS (₹)	0.12	—	-53.8%
Operating margin	49.8%	—	—

Full quarterly financials → Results calendar →

📢 Recent Corporate Announcements

Emrock Corporation Acquires 50.50% Stake in Newly Incorporated Emrock Lifescience LLP for Rs 50,500

🟡 NEUTRAL ⭐ 3/10

M&A 📅 05 Oct 2026, 07:32 PM

Emrock Corporation Limited has subscribed to a 50.50% capital contribution in Emrock Lifescience LLP, investing Rs 50,500 in cash. The target LLP was incorporated on October 5, 2026, with a total capital obligation of Rs 100,000 to enter pharmaceutical manufacturing, trading, and allied healthcare segments. This investment constitutes a related party transaction as Emrock Corporation's directors, Arjunbhai Jagdishbhai Patel and Parth Tulsibhai Patel, are designated partners in the LLP. While aligned with the company's stated strategy to diversify into pharmaceuticals, the initial financial commitment is immaterial relative to its net worth of Rs 24 Cr.

Acquired 50.50% capital contribution in Emrock Lifescience LLP
Cash consideration paid is Rs 50,500 out of total LLP capital obligation of Rs 100,000
Emrock Lifescience LLP was newly incorporated on October 5, 2026
Related party transaction with directors Arjunbhai Jagdishbhai Patel and Parth Tulsibhai Patel acting as designated partners

💡 Track subsequent capital outlays, capex commitments, or project execution timelines in Emrock Lifescience LLP as the business develops beyond initial incorporation.

Management Restructuring: Parth Tulsibhai Patel Resigns as Whole-time Director

🟡 NEUTRAL ⭐ 3/10

MANAGEMENT 📅 12 Aug 2026, 08:30 PM

Mr. Parth Tulsibhai Patel has resigned from his position as Whole-time Director of Emrock Corporation Ltd effective August 12, 2026. This move is described as part of a management restructuring and realignment of roles. Crucially, Mr. Patel will continue to serve in his capacities as Chairman of the Board, Director, and Chief Financial Officer (CFO). Given the company's small revenue base of Rs 2 Cr (TTM) against a market cap of Rs 616 Cr, leadership stability during its diversification into Solar and Pharma is notable.

Resignation of Mr. Parth Tulsibhai Patel as Whole-time Director effective August 12, 2026.
The individual continues to hold three key positions: Chairman, Director, and CFO.
Management cited 'restructuring and realignment of roles' as the primary reason for the change.
Company maintains a high promoter holding of 74.63% as of June 2026.
The company is currently transitioning from TDR facilitation to Solar Power and Pharmaceuticals.

💡 Investors should focus on the execution of the new Solar and Pharma segments, as the current TTM revenue of Rs 2 Cr is very low relative to the Rs 616 Cr valuation.

Emrock Corporation Approves Q1 FY27 Financial Results; Detailed Figures Awaited

🟡 NEUTRAL ⭐ 4/10

EARNINGS 📅 12 Aug 2026, 07:38 PM

Emrock Corporation (formerly Vaghani Techno Build) held a board meeting on August 12, 2026, to approve its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The filing confirms the approval of these results but does not include the specific profit and loss figures within the cover letter. Given the company's high P/E ratio of 540.0 and a low TTM revenue base of Rs 2 Cr, the actual performance in its new Solar and Pharma segments is critical for valuation support. Investors should monitor the full financial tables for signs of revenue scaling.

Board meeting held on August 12, 2026, concluded at 18:45 IST.
Approval of both standalone and consolidated unaudited results for the quarter ended June 30, 2026.
Company is currently valued at a P/E of 540.0 with a market cap of Rs 616 Cr.
TTM revenue remains low at Rs 2 Cr, highlighting the early stage of its business diversification.

💡 Investors should locate and review the detailed financial tables (P&L and Segment Results) to verify if the diversification into Solar and Pharma is generating meaningful revenue compared to the Rs 2 Cr TTM base.

Emrock Corporation Approves Q1 FY27 Standalone and Consolidated Financial Results

🟡 NEUTRAL ⭐ 6/10

EARNINGS 📅 12 Aug 2026, 07:37 PM

Emrock Corporation (formerly Vaghani Techno Build) approved its unaudited financial results for the quarter ended June 30, 2026, in a board meeting held on August 12, 2026. While the specific quarterly figures were not detailed in the cover letter, the company enters this period with a TTM revenue of just Rs 2 Cr and a high P/E of 540.0. The company is currently attempting to diversify from TDR facilitation into Solar Power and Pharmaceuticals. Investors should monitor the full financial tables for signs of revenue scaling in these new segments.

Board meeting conducted on August 12, 2026, lasting 1 hour and 45 minutes to approve results.
Approval granted for both Standalone and Consolidated unaudited results for Q1 FY27.
Company maintains a high promoter holding of 74.63% as of June 2026.
TTM revenue stands at a modest Rs 2 Cr against a market capitalization of Rs 616 Cr.

💡 Review the detailed P&L statement to verify if the new Solar and Pharma segments have commenced meaningful revenue generation to justify the current 540x P/E valuation.

Emrock Corporation Approves Q1 FY27 Unaudited Standalone Financial Results

🟡 NEUTRAL ⭐ 6/10

EARNINGS 📅 12 Aug 2026, 07:21 PM

Emrock Corporation (formerly Vaghani Techno Build) approved its standalone financial results for the quarter ended June 30, 2026, in a board meeting held on August 12, 2026. The company, which is currently diversifying from TDR facilitation into Solar Power and Pharmaceuticals, operates on a very small TTM revenue base of Rs 2 Cr. Despite the low revenue, the company commands a market capitalization of Rs 616 Cr with a high P/E ratio of 540.0. The board meeting concluded within 1 hour and 45 minutes, approving the results and the statutory auditor's limited review report.

Board meeting held on August 12, 2026, to approve results for the quarter ended June 30, 2026
Meeting duration was 1 hour and 45 minutes, starting at 17:00 and concluding at 18:45 IST
Company is transitioning its business model towards Solar Power and Pharmaceutical segments
TTM revenue stands at a modest Rs 2 Cr against a market cap of Rs 616 Cr
Promoter holding remains stable at 74.63% as per latest June 2026 data

💡 Investors should closely examine the detailed P&L statement to check for revenue contributions from the new Solar and Pharma segments, as the current valuation (P/E 540) is extremely high relative to historical earnings.

Emrock Corp Acquires 51% Stake in New Solar Subsidiary for Rs 51,000

🟢 POSITIVE ⭐ 6/10

M&A 📅 11 Aug 2026, 01:59 PM

Emrock Corporation has acquired a 51% controlling stake in Emrock Renewable Private Limited, a newly incorporated entity (August 10, 2026). The acquisition was completed via a nominal cash subscription of Rs 51,000 for 5,100 shares at face value. This move formalizes the company's previously stated strategy to diversify from TDR facilitation into the high-growth renewable energy and EV charging sectors. While the initial investment is negligible relative to the company's Rs 24 Cr net worth, it marks the operational start of a new business vertical.

Acquisition of 51% equity stake (5,100 shares) in Emrock Renewable Private Limited.
Initial cash consideration of Rs 51,000 at a face value of Rs 10 per share.
Target entity incorporated on August 10, 2026, with a total paid-up capital of Rs 1,00,000.
Business scope covers PV cells, solar modules, energy storage batteries, and EV charging equipment.
Transaction classified as a related party transaction due to common directors (Jatinkumar and Parth Patel).

💡 Investors should monitor future disclosures regarding capital expenditure plans and project timelines for the new solar subsidiary to assess if it can meaningfully contribute to the current TTM revenue of Rs 2 Cr.

Emrock Corporation to consider Q1 FY27 results on August 12, 2026

🟡 NEUTRAL ⭐ 3/10

BOARD_MEETING 📅 06 Aug 2026, 06:22 PM

Emrock Corporation Ltd has scheduled a board meeting for August 12, 2026, to approve its unaudited financial results for the quarter ended June 30, 2026. The company is currently operating on a very small scale with TTM revenue of just Rs 2 Cr, yet commands a market capitalization of Rs 609 Cr. The trading window for insiders has been closed since June 1, 2026, and will reopen 48 hours after the results are announced. Given the high P/E ratio of 534.0, the upcoming results will be critical for assessing the progress of its diversification into Solar and Pharma sectors.

Board meeting scheduled for August 12, 2026, to approve Q1 FY27 results
Trading window closed from June 1, 2026, until 48 hours post-result declaration
Company reported a TTM revenue of only Rs 2 Cr against a market cap of Rs 609 Cr
12-month price return stands at a significant 951.6% despite low revenue base
Promoter holding remains stable at 74.63% as of June 2026

💡 Monitor the financial results on August 12, 2026, specifically looking for revenue contributions from the new Solar Power and Pharmaceutical segments to justify the current valuation.

Emrock Corporation Reports 98.88% Demat Holding in June 2026 Share Reconciliation

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 21 Jul 2026, 03:46 PM

Emrock Corporation Ltd has submitted its Reconciliation of Share Capital Audit Report for the quarter ended June 30, 2026. The filing confirms that the total issued and listed capital remains unchanged at 1,58,20,000 shares. A significant majority of the shares (98.88%) are held in dematerialized form, with 90.81% in CDSL and 8.07% in NSDL. There were no discrepancies reported between the issued, listed, and total shares held by depositories.

Total issued and listed capital remains constant at 1,58,20,000 shares
90.81% of total shares (1,43,65,568 units) are held in CDSL demat form
8.07% of total shares (12,77,179 units) are held in NSDL demat form
Only 1.12% of shares (1,77,253 units) continue to be held in physical form
Zero dematerialization requests were pending beyond 21 days during the quarter

💡 This is a routine regulatory filing. Investors should monitor the company's execution of its diversification strategy into Solar Power and Pharmaceuticals, given the current high P/E ratio of 492.3 and low TTM revenue of Rs 2 Cr.

View All 531676 Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

Total revenue increased to INR 50.00 Lakhs in FY 2024-25 from NIL in the previous year. The company has widened its segments from Transfer Development Rights (TDR) to include Solar Power generation and Pharmaceuticals, though specific revenue splits per segment are not disclosed.

Profitability Margins

The company achieved a Net Profit Ratio of 25.23% in FY 2024-25, a significant recovery from -61.31% in the previous year. Return on Equity (ROE) improved to 2.32% from -1.41% YoY.

EBITDA Margin

Return on Capital Employed (ROCE) is 3% for FY 2024-25 compared to 1% in the previous year, indicating a slight improvement in core profitability from operations.

Capital Expenditure

Not disclosed in absolute INR Cr, but the company plans to import new machineries to improve quality standards and productivity.

Credit Rating & Borrowing

Not disclosed. However, the Debt-Equity ratio increased to 0.12 from 0 due to an increase in current borrowings.

⚙️ Operational Drivers

Raw Materials

Not disclosed. The company primarily provided services during the year, resulting in an inventory turnover ratio of 0.

Import Sources

The company intends to import new machineries if required to provide better results and cope with changing industry requirements, though specific countries are not named.

Capacity Expansion

Not disclosed for the company. Industry-wide, India aims for 500 GW of renewable capacity by 2030.

Raw Material Costs

Not disclosed as the company reported no purchases for both years in its trade payable turnover ratio calculation.

Manufacturing Efficiency

Capacity utilization metrics are not disclosed. The company focuses on cost reduction and quality improvement through new machinery.

📈 Strategic Growth

Growth Strategy

The company is diversifying its operations from TDR facilitation into Solar Power generation and Pharmaceuticals. It aims to achieve growth through operational improvements, cost reduction, and investing in human resources and training.

Products & Services

Facilitation of Transfer Development Rights (TDR) for real estate developers, Solar Power generation, and Pharmaceutical products.

Brand Portfolio

Emrock Corporation Limited (formerly Vaghani Techno-Build Limited).

New Products/Services

Solar Power generation and Pharmaceutical products are the newly added segments intended to increase profit levels.

🌍 External Factors

Industry Trends

The Indian real estate market is projected to reach US$ 5-7 trillion by 2047. India is 4th globally in solar capacity. The pharma sector supplies 40% of generic demand in the US, positioning the company in high-growth sectors.

Competitive Landscape

The TDR market is influenced by demand-supply caps and government regulations like the New Development Control & Promotion Regulation 2034.

Competitive Moat

The company's moat is based on diversification across three distinct high-growth sectors (Real Estate/TDR, Renewables, and Pharma) to mitigate cyclical risks in any single segment.

Macro Economic Sensitivity

The company is exposed to economic, regulatory, and taxation risks. TDR demand is sensitive to the overall real estate market health.

Consumer Behavior

Increased global preference for low-priced, high-quality Indian medicines and government support for renewable energy are driving demand shifts.

⚖️ Regulatory & Governance

Industry Regulations

Operations are affected by SEBI (LODR) Regulations, the Companies Act 2013, and the New Development Control & Promotion Regulation 2034. Solar power is subject to state-level tariff changes and PPA renegotiations.